000143921 001__ 143921
000143921 005__ 20240229112612.0
000143921 0247_ $$2doi$$a10.1186/s13014-019-1308-y
000143921 0247_ $$2pmid$$apmid:31167658
000143921 0247_ $$2pmc$$apmc:PMC6551911
000143921 0247_ $$2altmetric$$aaltmetric:62026901
000143921 037__ $$aDKFZ-2019-01479
000143921 041__ $$aeng
000143921 082__ $$a610
000143921 1001_ $$00000-0001-8709-7252$$aCorradini, S.$$b0
000143921 245__ $$aMR-guidance in clinical reality: current treatment challenges and future perspectives.
000143921 260__ $$aLondon$$bBioMed Central$$c2019
000143921 3367_ $$2DRIVER$$aarticle
000143921 3367_ $$2DataCite$$aOutput Types/Journal article
000143921 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1560345686_923$$xReview Article
000143921 3367_ $$2BibTeX$$aARTICLE
000143921 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143921 3367_ $$00$$2EndNote$$aJournal Article
000143921 520__ $$aMagnetic Resonance-guided radiotherapy (MRgRT) marks the beginning of a new era. MR is a versatile and suitable imaging modality for radiotherapy, as it enables direct visualization of the tumor and the surrounding organs at risk. Moreover, MRgRT provides real-time imaging to characterize and eventually track anatomical motion. Nevertheless, the successful translation of new technologies into clinical practice remains challenging. To date, the initial availability of next-generation hybrid MR-linac (MRL) systems is still limited and therefore, the focus of the present preview was on the initial applicability in current clinical practice and on future perspectives of this new technology for different treatment sites.MRgRT can be considered a groundbreaking new technology that is capable of creating new perspectives towards an individualized, patient-oriented planning and treatment approach, especially due to the ability to use daily online adaptation strategies. Furthermore, MRL systems overcome the limitations of conventional image-guided radiotherapy, especially in soft tissue, where target and organs at risk need accurate definition. Nevertheless, some concerns remain regarding the additional time needed to re-optimize dose distributions online, the reliability of the gating and tracking procedures and the interpretation of functional MR imaging markers and their potential changes during the course of treatment. Due to its continuous technological improvement and rapid clinical large-scale application in several anatomical settings, further studies may confirm the potential disruptive role of MRgRT in the evolving oncological environment.
000143921 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000143921 588__ $$aDataset connected to CrossRef, PubMed,
000143921 7001_ $$aAlongi, F.$$b1
000143921 7001_ $$aAndratschke, N.$$b2
000143921 7001_ $$aBelka, C.$$b3
000143921 7001_ $$aBoldrini, L.$$b4
000143921 7001_ $$aCellini, F.$$b5
000143921 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b6$$udkfz
000143921 7001_ $$aGuckenberger, M.$$b7
000143921 7001_ $$0P:(DE-HGF)0$$aHörner-Rieber, J.$$b8
000143921 7001_ $$aLagerwaard, F. J.$$b9
000143921 7001_ $$aMazzola, R.$$b10
000143921 7001_ $$aPalacios, M. A.$$b11
000143921 7001_ $$aPhilippens, M. E. P.$$b12
000143921 7001_ $$aRaaijmakers, C. P. J.$$b13
000143921 7001_ $$aTerhaard, C. H. J.$$b14
000143921 7001_ $$aValentini, V.$$b15
000143921 7001_ $$aNiyazi, M.$$b16
000143921 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-019-1308-y$$gVol. 14, no. 1, p. 92$$n1$$p92$$tRadiation oncology$$v14$$x1748-717X$$y2019
000143921 909CO $$ooai:inrepo02.dkfz.de:143921$$pVDB
000143921 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000143921 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143921 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000143921 9141_ $$y2019
000143921 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143921 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143921 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143921 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143921 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143921 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143921 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143921 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143921 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143921 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143921 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143921 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143921 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143921 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143921 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x0
000143921 980__ $$ajournal
000143921 980__ $$aVDB
000143921 980__ $$aI:(DE-He78)E050-20160331
000143921 980__ $$aUNRESTRICTED